Hikal has formally entered commercial-scale beauty and personal-care manufacturing, starting production at a new cGMP-compliant multipurpose facility at its Panoli site in Gujarat.
The move matters because the Indian beauty story is usually told through consumer brands, marketplaces and salons. Hikal’s entry sits further upstream: in the specialty ingredients and manufacturing infrastructure that determine what brands can formulate, source and scale.
Its initial focus is skincare, particularly second-generation UV filters, putting the listed specialty-chemicals company into a category being reshaped by rising sunscreen usage, tighter performance expectations and evolving regulation across global markets.
What happened
In a September 22 exchange filing, Hikal said it had successfully started commercial production of personal-care products after commissioning a dedicated cGMP-compliant facility at Panoli.
The company repurposed an existing manufacturing asset for the beauty and personal-care business. It said the first production batches have been manufactured, product samples have been validated with customers and the initial response has created what management described as positive market pull.
Hikal’s starting portfolio centres on second-generation UV filters. The company says these ingredients are intended to offer improved performance and closer alignment with changing consumer preferences and regulatory requirements in major markets. Products are undergoing approvals with global customers.
Management framed personal care as a new long-term growth platform alongside Hikal’s established pharmaceutical, crop-protection and animal-health businesses.
Why it matters
India’s beauty industry cannot scale on branding alone. Behind every sunscreen, serum, hair treatment or cosmetic product is an ingredient and manufacturing supply chain that must meet quality, documentation, consistency and regulatory requirements.
UV filters are particularly strategic. Sunscreen has moved from a seasonal or dermatologist-led purchase toward a more mainstream skincare step, while brands increasingly compete on texture, protection profile and formulation elegance. That creates demand not only for finished sunscreens but for specialised inputs that allow formulators to differentiate them.
Hikal enters with capabilities built in regulated chemical and pharmaceutical manufacturing. If those capabilities translate well to cosmetics, India could capture more value in the upstream beauty chain instead of relying heavily on imported specialty ingredients.
The development is also relevant to domestic contract manufacturers and emerging brands. A deeper local ingredient ecosystem can shorten sourcing chains, support formulation experimentation and potentially improve supply resilience.
What to watch
The first commercial question is customer conversion. Hikal has disclosed validation and encouraging feedback, but not named customers or personal-care revenue targets.
AdvertisR will watch customer approvals, capacity utilisation, export versus domestic sales, the expansion of the UV-filter portfolio and whether Hikal moves into additional active or functional cosmetic ingredients.
If the business scales, beauty ingredients could become a more visible investable layer of India’s beauty economy rather than an invisible input behind consumer brands.
Source note: Hikal Regulation 30 press release filed with BSE/NSE on September 22, 2026; corroborated by Indian Pharma Post. Exchange filing mirror · Indian Pharma Post.
